China Journal of Leprosy and Skin Diseases ›› 2026, Vol. 42 ›› Issue (3): 190-193.doi: 10.12144/zgmfskin202603190

• Clinical Researches • Previous Articles     Next Articles

Upadacitinib in the treatment of Hailey-Hailey disease: a case report and literature review

HU Yiyang1,2,3, WANG Yulin1,2,3, HU Jie1,2,3, ZHAO Qi1,2,3, WANG Ruyi1,2,3, LI Chengyu3, CAI Jia3, LI Xiangning3, TANG Lili1,2,3, FAN Xing1,2,3   

  1. 1 Department of Dermatology, The First Affiliated Hospital of Anhui Medical University, Hefei 230022, China; 2 Key Laboratory of Dermatology(Anhui Medical University), Ministry of Education, Hefei 230022, China; 3 Anhui Medical University, Hefei 230032, China
  • Online:2026-03-15 Published:2026-03-10

PDF (PC)

1

Like

Abstract: The patient, a 50-year-old male with Hailey-Hailey disease, had previously been treated with medications such as methylprednisolone tablets and compound glycyrrhizin tablets, but the response was unsatisfactory. Previous literature has reported cases of upadacitinib being used to treat Hailey-Hailey disease. After obtaining informed consent from the patient, he was administered upadacitinib 15 mg once daily. Following two weeks of treatment, the skin lesions showed significant drying and regression. After one additional month of maintenance therapy, the skin lesions continued to improve with no new lesions emerging. At the two-month follow-up, the skin lesions remained stable without any adverse reactions.

Key words: upadacitinib, Hailey-Hailey disease, JAK inhibitor